

VU Research Portal

Incretin-based drugs and the kidney in type 2 diabetes

Tonneijck, L.

2018

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Tonneijck, L. (2018). *Incretin-based drugs and the kidney in type 2 diabetes: Moving from safety to protection*. [, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of contents

Chapter 1	General introduction and outline of the thesis <i>Based on: Nat Rev Nephrol 2017; 13: 605-28</i> <i>BMJ Open 2015; 5: e009579</i>	11
Chapter 2	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors <i>Lancet Diabetes Endocrinol 2015; 3: 367-81</i>	39
Chapter 3	Glomerular hyperfiltration in diabetes: mechanisms, clinical significance and treatment <i>J Am Soc Nephrol 2017; 28: 1023-39</i>	69
Chapter 4	Combining incretin-based drugs and RAAS inhibitors: more cons than pros? <i>Lancet Diabetes Endocrinol 2014; 2: 684-5</i>	101
Chapter 5	Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men <i>Diabetes Obes Metab 2016; 18: 178-85</i>	109
Chapter 6	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial <i>Diabetologia 2016; 59: 1412-21</i>	129
Chapter 7	Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomised, double blind, placebo-controlled trial <i>Diabetes Care 2016; 39: 2042-50</i>	153
Chapter 8	Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glisulins in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial <i>Diabetes Obes Metab 2017; 19: 1669-80</i>	177
Chapter 9	Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus <i>Accepted in: Am J Physiol Renal Physiol</i>	211
Chapter 10	Lixisenatide versus insulin glulisine on fasting and postbreakfast systemic haemodynamics in type 2 diabetes mellitus patients <i>Hypertension 2018; 72: 314-22</i>	231
Chapter 11	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: <i>post-hoc</i> analyses of four clinical trials <i>Diabetes Obes Metab 2018; 20: 1235-45</i>	257

Chapter 12	Liraglutide and renal outcomes in type 2 diabetes <i>N Engl J Med 2017; 377: 2195</i>	285
Chapter 13	Summary and general discussion <i>Based on: Nat Rev Nephrol 2017; 13: 605-28</i>	293
Appendix	Dutch summary – Nederlandse samenvatting	345
	Bibliography	355
	List of co-authors affiliations	361
	Acknowledgements – Dankwoord	365
	Biography – Biografie	371